Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Adipocyte FABP (FABP4) Mouse ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Adipocyte-type fatty acid-binding protein, A-FABP, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, ALBP, FABP4
  • Species:Mouse
Please select your region to see available products and prices.
Cat. No. Size Price

RD291036200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody



Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.78–50 ng/ml

Limit of Detection

0.23 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 8.7%

Inter-assay (Run-to-Run)

n = 4; CV = 7.1%

Dilution Linearity



  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • human Non-detectable
  • monkey Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • mouse Yes
  • rat Yes (recommended dilution 1:16)


  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures total AFABP in mouse serum
  • Assay format is 96 wells
  • Standard is native serum protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Animal studies


Adipocyte fatty acid binding protein AFABP is a 15 kDa member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds (bile acids or retinoids) in an internal cavity. AFABP is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells . In mice, targeted mutations in AFABP provide significant protection from hyperinsulinemia and insulin resistance in the context of both dietary and genetic obesity. Adipocytes obtained from AFABP-deficient mice also have reduced efficiency of lipolysis in vitro and in vivo, and these mice exhibited moderately improved systemic dyslipidemia. Recent studies also demonstrated AFABP expression in macrophages upon differentiation and activation. In these cells, AFABP modulates inflammatory responses and cholesterol ester accumulation, and total or macrophage-specific AFABP deficiency confers dramatic protection against atherosclerosis in the apoE-/- mice. These results indicate a central role for AFABP in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages.

Product References (5)


  • Shrestha S, Sunaga H, Hanaoka H, Yamaguchi A, Kuwahara S, Umbarawan Y,Nakajima K, Machida T, Murakami M, Saito A, Tsushima Y, Kurabayashi M, Iso T.Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption. Sci Rep. 2018 Nov 6;8(1):16451. doi:10.1038/s41598-018-34902-w. PubMed PMID: 30401801; PubMed Central PMCID:PMC6219568. See more on PubMed
  • Shu L, Hoo RL, Wu X, Pan Y, Lee IP, Cheong LY, Bornstein SR, Rong X, Guo J, XuA. A-FABP mediates adaptive thermogenesis by promoting intracellular activationof thyroid hormones in brown adipocytes. Nat Commun. 2017 Jan 27;8:14147. doi:10.1038/ncomms14147. PubMed PMID: 28128199; PubMed Central PMCID: PMC5290165. See more on PubMed
  • Vila IK, Badin PM, Marques MA, Monbrun L, Lefort C, Mir L, Louche K, Bourlier V, Roussel B, Gui P, Grober J, Štich V, Rossmeislová L, Zakaroff-Girard A,Bouloumié A, Viguerie N, Moro C, Tavernier G, Langin D. Immune cell Toll-likereceptor 4 mediates the development of obesity- and endotoxemia-associatedadipose tissue fibrosis. Cell Rep. 2014 May 22;7(4):1116-29. doi:10.1016/j.celrep.2014.03.062. Epub 2014 May 1. PubMed PMID: 24794440. See more on PubMed
  • Villeneuve J, Bassaganyas L, Lepreux S, Chiritoiu M, Costet P, Ripoche J,Malhotra V, Schekman R. Unconventional secretion of FABP4 by endosomes andsecretory lysosomes. J Cell Biol. 2018 Feb 5;217(2):649-665. doi:10.1083/jcb.201705047. Epub 2017 Dec 6. PubMed PMID: 29212659; PubMed CentralPMCID: PMC5800802. See more on PubMed
  • Yang R, Castriota G, Chen Y, Cleary MA, Ellsworth K, Shin MK, Tran JL, VogtTF, Wu M, Xu S, Yang X, Zhang BB, Berger JP, Qureshi SA. RNAi-mediated germlineknockdown of FABP4 increases body weight but does not improve the derangednutrient metabolism of diet-induced obese mice. Int J Obes (Lond). 2011Feb;35(2):217-25. doi: 10.1038/ijo.2010.128. Epub 2010 Jul 6. PubMed PMID:20603627; PubMed Central PMCID: PMC3056343. See more on PubMed
Summary References (15)

References to Adipocyte Fatty Acid Binding Protein

  • Makowski L, Brittingham KC, Reynolds JM, Suttles J and Hotamisligil GS: The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity. J Biol Chem. 2005 Apr 1.280(13):12888–95.
  • Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, AtsumiG, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA and Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism, Volume 1, Issue 2, February 2005, Pages 107–119.
  • Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004 Sep 14;110(11):1492–8.
  • Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, Lundback T, Rondahl L, Barf T: Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445–8.
  • Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF, Ferrell RE: Genetic variation in fatty acid-binding protein-4 and peroxisome proliferatoractivated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism. 2004 Mar;53(3):303–9.
  • Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA: Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem. 2003 Nov 28;278(48):47636–43.
  • Hertzel AV, Bennaars-Eiden A, Bernlohr DA: Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J Lipid Res. 2002 Dec;43(12):2105–11.
  • Fu Y, Luo N, Lopes-Virella MF, Garvey WT: The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002 Dec;165(2):259–69.
  • Storch J, Veerkamp JH, Hsu KT: Similar mechanisms of fatty acid transfer from human anal rodent fatty acid-binding proteins to membranes: liver, intestine, heart muscle, and adipose tissue FABPs. Mol Cell Biochem. 2002 Oct;239(1–2):25–33.
  • Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M: Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int J Obes Relat Metab Disord. 2002 Oct;26(10):1379–85.
  • Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1686–91.
  • Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001 Oct;44(10):1268–73.
  • Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS: Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes. 1999 Oct;48(10):1987–94.
  • Coe NR, Simpson MA, Bernlohr DA: Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res. 1999 May;40(5):967–72.
  • Baxa CA, Sha RS, Buelt MK, Smith AJ, MatareseV, Chinander LL, Boundy KL and Bernlohr DA: Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry. 1989; 28 (22), 8683–8690.
Related Products Docs